Jazz Pharmaceuticals has been granted a patent for a method to treat epileptic seizures using cannabidivarin (CBDV) and its combinations with other phytocannabinoids, including tetrahydrocannabivarin (THCV) and cannabidiol (CBD), alongside standard anti-epileptic drugs like ethosuximide and valproate. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of epilepsy using cannabidivarin (cbdv) and combinations
A recently granted patent (US12023305B2) outlines a method for treating epileptic seizures through the administration of a cannabis plant extract rich in cannabidivarin (CBDV). The extract is characterized by a composition where the phytocannabinoid component constitutes over 50% of the total weight, with CBDV making up more than 40% of the extract. Additionally, the extract includes cannabidiol (CBD) as a secondary phytocannabinoid, present in amounts ranging from 5% to 27%. The formulation also contains a non-phytocannabinoid component, which is primarily composed of monoterpenes and sesquiterpenes, with specific weight percentages defined for each fraction.
Further claims within the patent specify variations in the composition of the cannabis extract, including the potential inclusion of tetrahydrocannabivarin (THCV). The phytocannabinoid component can range from 64% to 78% of the extract, with CBDV constituting 52% to 64% of this fraction. The patent also details the proportions of CBD and THCV within the phytocannabinoid component, as well as the specific makeup of the monoterpene fraction, which includes a principal monoterpene making up 61% to 75% of the total weight. This patent presents a structured approach to utilizing cannabis extracts for therapeutic purposes, particularly in the management of epileptic seizures.
To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
